Global Treatment Resistant Depression Market

Treatment Resistant Depression Comprehensive Study by Signs of Depression (Less interest in activities, Less energetic, Trouble concentrating, Changes in appetite), Medication (Selective serotonin reuptake inhibitors (SSRIs), Serotonin and norepinephrine reuptake inhibitors (SNRIs), Atypical antidepressants, Tricyclic antidepressants, Other medication), Forms of Treatment (Cognitive-behavioral therapy, Interpersonal therapy, Psychodynamic therapy) Players and Region - Global Market Outlook to 2026

Treatment Resistant Depression Market by XX Submarkets | Forecast Years 2021-2026  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Treatment Resistant Depression Market Overview:
TRD is a relatively common occurrence in clinical practice.Treatment-resistant depression, a complex clinical problem caused by multiple risk factors, is targeted by integrated therapeutic strategies, which include optimization of medication and augmentation with non-antidepressants, psychosocial and cultural therapies. The complexity of treatment for TRD reflects the diverse nature of the disorder, and the provider should be careful to make an accurate diagnosis before treatment. Treatment-resistant depression is a difficult condition to treat. Patients with the disorder should interactively share their inner experiences with the treating expert and be able to ask freely any questions related to risk factors underlying treatment-resistant depression, duration of treatment, severity of side effect, suicidal thoughts and attempts, non-suicidal self-injurious behaviors, and intolerance issues.

Growth Drivers
  • Rising prevalence of the depressive disorder

Roadblocks
  • Lack of awareness about depression among people

Opportunities
  • High governmental healthcare expenditure

Challenges
  • Lack of trained professionals
  • High-cost of treatment


Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Bristol Myers Squibb Company (United States), Janssen Pharmaceuticals, Inc. (Belgium), Otsuka Pharmaceutical Co., Ltd. (Japan), Mylan Pharmaceuticals, Inc. (United States), Pfizer, Inc (United State), Novartis AG (Switzerland), Eli Lilly and Company (United States), Wyeth (United States) and Validus Pharmaceuticals LLC (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Treatment Resistant Depression market by 2026. Considering Market by Signs of Depression , the sub-segment i.e. Less interest in activities will boost the Treatment Resistant Depression market. Considering Market by Medication , the sub-segment i.e. Selective serotonin reuptake inhibitors (SSRIs) will boost the Treatment Resistant Depression market. Considering Market by Forms of Treatment, the sub-segment i.e. Cognitive-behavioral therapy will boost the Treatment Resistant Depression market.

On 3 August 2020 The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application for SPRAVATO CIII nasal spray, taken with an oral antidepressant, to treat depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.1 SPRAVATO is the first and only approved medicine that has been shown to reduce depressive symptoms within 24 hours,1 providing a new option for significant symptom relief until a longer-term, comprehensive treatment plan can take effect.

What Can be Explored with the Treatment Resistant Depression Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Treatment Resistant Depression Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Treatment Resistant Depression
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Treatment Resistant Depression market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Treatment Resistant Depression market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Treatment-Resistant Depression Provider, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Signs of Depression
  • Less interest in activities
  • Less energetic
  • Trouble concentrating
  • Changes in appetite

By Medication
  • Selective serotonin reuptake inhibitors (SSRIs)
  • Serotonin and norepinephrine reuptake inhibitors (SNRIs)
  • Atypical antidepressants
  • Tricyclic antidepressants
  • Other medication

By Forms of Treatment
  • Cognitive-behavioral therapy
  • Interpersonal therapy
  • Psychodynamic therapy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising prevalence of the depressive disorder
    • 3.3. Market Challenges
      • 3.3.1. Lack of trained professionals
      • 3.3.2. High-cost of treatment
    • 3.4. Market Trends
      • 3.4.1. High risk of depression in teenager and older adults
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Treatment Resistant Depression, by Signs of Depression , Medication , Forms of Treatment and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Treatment Resistant Depression (Value)
      • 5.2.1. Global Treatment Resistant Depression by: Forms of Treatment (Value)
        • 5.2.1.1. Cognitive-behavioral therapy
        • 5.2.1.2. Interpersonal therapy
        • 5.2.1.3. Psychodynamic therapy
      • 5.2.2. Global Treatment Resistant Depression Region
        • 5.2.2.1. South America
          • 5.2.2.1.1. Brazil
          • 5.2.2.1.2. Argentina
          • 5.2.2.1.3. Rest of South America
        • 5.2.2.2. Asia Pacific
          • 5.2.2.2.1. China
          • 5.2.2.2.2. Japan
          • 5.2.2.2.3. India
          • 5.2.2.2.4. South Korea
          • 5.2.2.2.5. Taiwan
          • 5.2.2.2.6. Australia
          • 5.2.2.2.7. Rest of Asia-Pacific
        • 5.2.2.3. Europe
          • 5.2.2.3.1. Germany
          • 5.2.2.3.2. France
          • 5.2.2.3.3. Italy
          • 5.2.2.3.4. United Kingdom
          • 5.2.2.3.5. Netherlands
          • 5.2.2.3.6. Rest of Europe
        • 5.2.2.4. MEA
          • 5.2.2.4.1. Middle East
          • 5.2.2.4.2. Africa
        • 5.2.2.5. North America
          • 5.2.2.5.1. United States
          • 5.2.2.5.2. Canada
          • 5.2.2.5.3. Mexico
  • 6. Treatment Resistant Depression: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bristol Myers Squibb Company (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Janssen Pharmaceuticals, Inc. (Belgium)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Otsuka Pharmaceutical Co., Ltd. (Japan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Mylan Pharmaceuticals, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer, Inc (United State)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Eli Lilly and Company (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Wyeth (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Validus Pharmaceuticals LLC (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Treatment Resistant Depression Sale, by Signs of Depression , Medication , Forms of Treatment and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Treatment Resistant Depression (Value)
      • 7.2.1. Global Treatment Resistant Depression by: Forms of Treatment (Value)
        • 7.2.1.1. Cognitive-behavioral therapy
        • 7.2.1.2. Interpersonal therapy
        • 7.2.1.3. Psychodynamic therapy
      • 7.2.2. Global Treatment Resistant Depression Region
        • 7.2.2.1. South America
          • 7.2.2.1.1. Brazil
          • 7.2.2.1.2. Argentina
          • 7.2.2.1.3. Rest of South America
        • 7.2.2.2. Asia Pacific
          • 7.2.2.2.1. China
          • 7.2.2.2.2. Japan
          • 7.2.2.2.3. India
          • 7.2.2.2.4. South Korea
          • 7.2.2.2.5. Taiwan
          • 7.2.2.2.6. Australia
          • 7.2.2.2.7. Rest of Asia-Pacific
        • 7.2.2.3. Europe
          • 7.2.2.3.1. Germany
          • 7.2.2.3.2. France
          • 7.2.2.3.3. Italy
          • 7.2.2.3.4. United Kingdom
          • 7.2.2.3.5. Netherlands
          • 7.2.2.3.6. Rest of Europe
        • 7.2.2.4. MEA
          • 7.2.2.4.1. Middle East
          • 7.2.2.4.2. Africa
        • 7.2.2.5. North America
          • 7.2.2.5.1. United States
          • 7.2.2.5.2. Canada
          • 7.2.2.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Treatment Resistant Depression: by Forms of Treatment(USD Million)
  • Table 2. Treatment Resistant Depression Cognitive-behavioral therapy , by Region USD Million (2015-2020)
  • Table 3. Treatment Resistant Depression Interpersonal therapy , by Region USD Million (2015-2020)
  • Table 4. Treatment Resistant Depression Psychodynamic therapy , by Region USD Million (2015-2020)
  • Table 5. South America Treatment Resistant Depression, by Country USD Million (2015-2020)
  • Table 6. South America Treatment Resistant Depression, by Signs of Depression USD Million (2015-2020)
  • Table 7. South America Treatment Resistant Depression, by Medication USD Million (2015-2020)
  • Table 8. South America Treatment Resistant Depression, by Forms of Treatment USD Million (2015-2020)
  • Table 9. Brazil Treatment Resistant Depression, by Signs of Depression USD Million (2015-2020)
  • Table 10. Brazil Treatment Resistant Depression, by Medication USD Million (2015-2020)
  • Table 11. Brazil Treatment Resistant Depression, by Forms of Treatment USD Million (2015-2020)
  • Table 12. Argentina Treatment Resistant Depression, by Signs of Depression USD Million (2015-2020)
  • Table 13. Argentina Treatment Resistant Depression, by Medication USD Million (2015-2020)
  • Table 14. Argentina Treatment Resistant Depression, by Forms of Treatment USD Million (2015-2020)
  • Table 15. Rest of South America Treatment Resistant Depression, by Signs of Depression USD Million (2015-2020)
  • Table 16. Rest of South America Treatment Resistant Depression, by Medication USD Million (2015-2020)
  • Table 17. Rest of South America Treatment Resistant Depression, by Forms of Treatment USD Million (2015-2020)
  • Table 18. Asia Pacific Treatment Resistant Depression, by Country USD Million (2015-2020)
  • Table 19. Asia Pacific Treatment Resistant Depression, by Signs of Depression USD Million (2015-2020)
  • Table 20. Asia Pacific Treatment Resistant Depression, by Medication USD Million (2015-2020)
  • Table 21. Asia Pacific Treatment Resistant Depression, by Forms of Treatment USD Million (2015-2020)
  • Table 22. China Treatment Resistant Depression, by Signs of Depression USD Million (2015-2020)
  • Table 23. China Treatment Resistant Depression, by Medication USD Million (2015-2020)
  • Table 24. China Treatment Resistant Depression, by Forms of Treatment USD Million (2015-2020)
  • Table 25. Japan Treatment Resistant Depression, by Signs of Depression USD Million (2015-2020)
  • Table 26. Japan Treatment Resistant Depression, by Medication USD Million (2015-2020)
  • Table 27. Japan Treatment Resistant Depression, by Forms of Treatment USD Million (2015-2020)
  • Table 28. India Treatment Resistant Depression, by Signs of Depression USD Million (2015-2020)
  • Table 29. India Treatment Resistant Depression, by Medication USD Million (2015-2020)
  • Table 30. India Treatment Resistant Depression, by Forms of Treatment USD Million (2015-2020)
  • Table 31. South Korea Treatment Resistant Depression, by Signs of Depression USD Million (2015-2020)
  • Table 32. South Korea Treatment Resistant Depression, by Medication USD Million (2015-2020)
  • Table 33. South Korea Treatment Resistant Depression, by Forms of Treatment USD Million (2015-2020)
  • Table 34. Taiwan Treatment Resistant Depression, by Signs of Depression USD Million (2015-2020)
  • Table 35. Taiwan Treatment Resistant Depression, by Medication USD Million (2015-2020)
  • Table 36. Taiwan Treatment Resistant Depression, by Forms of Treatment USD Million (2015-2020)
  • Table 37. Australia Treatment Resistant Depression, by Signs of Depression USD Million (2015-2020)
  • Table 38. Australia Treatment Resistant Depression, by Medication USD Million (2015-2020)
  • Table 39. Australia Treatment Resistant Depression, by Forms of Treatment USD Million (2015-2020)
  • Table 40. Rest of Asia-Pacific Treatment Resistant Depression, by Signs of Depression USD Million (2015-2020)
  • Table 41. Rest of Asia-Pacific Treatment Resistant Depression, by Medication USD Million (2015-2020)
  • Table 42. Rest of Asia-Pacific Treatment Resistant Depression, by Forms of Treatment USD Million (2015-2020)
  • Table 43. Europe Treatment Resistant Depression, by Country USD Million (2015-2020)
  • Table 44. Europe Treatment Resistant Depression, by Signs of Depression USD Million (2015-2020)
  • Table 45. Europe Treatment Resistant Depression, by Medication USD Million (2015-2020)
  • Table 46. Europe Treatment Resistant Depression, by Forms of Treatment USD Million (2015-2020)
  • Table 47. Germany Treatment Resistant Depression, by Signs of Depression USD Million (2015-2020)
  • Table 48. Germany Treatment Resistant Depression, by Medication USD Million (2015-2020)
  • Table 49. Germany Treatment Resistant Depression, by Forms of Treatment USD Million (2015-2020)
  • Table 50. France Treatment Resistant Depression, by Signs of Depression USD Million (2015-2020)
  • Table 51. France Treatment Resistant Depression, by Medication USD Million (2015-2020)
  • Table 52. France Treatment Resistant Depression, by Forms of Treatment USD Million (2015-2020)
  • Table 53. Italy Treatment Resistant Depression, by Signs of Depression USD Million (2015-2020)
  • Table 54. Italy Treatment Resistant Depression, by Medication USD Million (2015-2020)
  • Table 55. Italy Treatment Resistant Depression, by Forms of Treatment USD Million (2015-2020)
  • Table 56. United Kingdom Treatment Resistant Depression, by Signs of Depression USD Million (2015-2020)
  • Table 57. United Kingdom Treatment Resistant Depression, by Medication USD Million (2015-2020)
  • Table 58. United Kingdom Treatment Resistant Depression, by Forms of Treatment USD Million (2015-2020)
  • Table 59. Netherlands Treatment Resistant Depression, by Signs of Depression USD Million (2015-2020)
  • Table 60. Netherlands Treatment Resistant Depression, by Medication USD Million (2015-2020)
  • Table 61. Netherlands Treatment Resistant Depression, by Forms of Treatment USD Million (2015-2020)
  • Table 62. Rest of Europe Treatment Resistant Depression, by Signs of Depression USD Million (2015-2020)
  • Table 63. Rest of Europe Treatment Resistant Depression, by Medication USD Million (2015-2020)
  • Table 64. Rest of Europe Treatment Resistant Depression, by Forms of Treatment USD Million (2015-2020)
  • Table 65. MEA Treatment Resistant Depression, by Country USD Million (2015-2020)
  • Table 66. MEA Treatment Resistant Depression, by Signs of Depression USD Million (2015-2020)
  • Table 67. MEA Treatment Resistant Depression, by Medication USD Million (2015-2020)
  • Table 68. MEA Treatment Resistant Depression, by Forms of Treatment USD Million (2015-2020)
  • Table 69. Middle East Treatment Resistant Depression, by Signs of Depression USD Million (2015-2020)
  • Table 70. Middle East Treatment Resistant Depression, by Medication USD Million (2015-2020)
  • Table 71. Middle East Treatment Resistant Depression, by Forms of Treatment USD Million (2015-2020)
  • Table 72. Africa Treatment Resistant Depression, by Signs of Depression USD Million (2015-2020)
  • Table 73. Africa Treatment Resistant Depression, by Medication USD Million (2015-2020)
  • Table 74. Africa Treatment Resistant Depression, by Forms of Treatment USD Million (2015-2020)
  • Table 75. North America Treatment Resistant Depression, by Country USD Million (2015-2020)
  • Table 76. North America Treatment Resistant Depression, by Signs of Depression USD Million (2015-2020)
  • Table 77. North America Treatment Resistant Depression, by Medication USD Million (2015-2020)
  • Table 78. North America Treatment Resistant Depression, by Forms of Treatment USD Million (2015-2020)
  • Table 79. United States Treatment Resistant Depression, by Signs of Depression USD Million (2015-2020)
  • Table 80. United States Treatment Resistant Depression, by Medication USD Million (2015-2020)
  • Table 81. United States Treatment Resistant Depression, by Forms of Treatment USD Million (2015-2020)
  • Table 82. Canada Treatment Resistant Depression, by Signs of Depression USD Million (2015-2020)
  • Table 83. Canada Treatment Resistant Depression, by Medication USD Million (2015-2020)
  • Table 84. Canada Treatment Resistant Depression, by Forms of Treatment USD Million (2015-2020)
  • Table 85. Mexico Treatment Resistant Depression, by Signs of Depression USD Million (2015-2020)
  • Table 86. Mexico Treatment Resistant Depression, by Medication USD Million (2015-2020)
  • Table 87. Mexico Treatment Resistant Depression, by Forms of Treatment USD Million (2015-2020)
  • Table 88. Company Basic Information, Sales Area and Its Competitors
  • Table 89. Company Basic Information, Sales Area and Its Competitors
  • Table 90. Company Basic Information, Sales Area and Its Competitors
  • Table 91. Company Basic Information, Sales Area and Its Competitors
  • Table 92. Company Basic Information, Sales Area and Its Competitors
  • Table 93. Company Basic Information, Sales Area and Its Competitors
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Treatment Resistant Depression: by Forms of Treatment(USD Million)
  • Table 98. Treatment Resistant Depression Cognitive-behavioral therapy , by Region USD Million (2021-2026)
  • Table 99. Treatment Resistant Depression Interpersonal therapy , by Region USD Million (2021-2026)
  • Table 100. Treatment Resistant Depression Psychodynamic therapy , by Region USD Million (2021-2026)
  • Table 101. South America Treatment Resistant Depression, by Country USD Million (2021-2026)
  • Table 102. South America Treatment Resistant Depression, by Signs of Depression USD Million (2021-2026)
  • Table 103. South America Treatment Resistant Depression, by Medication USD Million (2021-2026)
  • Table 104. South America Treatment Resistant Depression, by Forms of Treatment USD Million (2021-2026)
  • Table 105. Brazil Treatment Resistant Depression, by Signs of Depression USD Million (2021-2026)
  • Table 106. Brazil Treatment Resistant Depression, by Medication USD Million (2021-2026)
  • Table 107. Brazil Treatment Resistant Depression, by Forms of Treatment USD Million (2021-2026)
  • Table 108. Argentina Treatment Resistant Depression, by Signs of Depression USD Million (2021-2026)
  • Table 109. Argentina Treatment Resistant Depression, by Medication USD Million (2021-2026)
  • Table 110. Argentina Treatment Resistant Depression, by Forms of Treatment USD Million (2021-2026)
  • Table 111. Rest of South America Treatment Resistant Depression, by Signs of Depression USD Million (2021-2026)
  • Table 112. Rest of South America Treatment Resistant Depression, by Medication USD Million (2021-2026)
  • Table 113. Rest of South America Treatment Resistant Depression, by Forms of Treatment USD Million (2021-2026)
  • Table 114. Asia Pacific Treatment Resistant Depression, by Country USD Million (2021-2026)
  • Table 115. Asia Pacific Treatment Resistant Depression, by Signs of Depression USD Million (2021-2026)
  • Table 116. Asia Pacific Treatment Resistant Depression, by Medication USD Million (2021-2026)
  • Table 117. Asia Pacific Treatment Resistant Depression, by Forms of Treatment USD Million (2021-2026)
  • Table 118. China Treatment Resistant Depression, by Signs of Depression USD Million (2021-2026)
  • Table 119. China Treatment Resistant Depression, by Medication USD Million (2021-2026)
  • Table 120. China Treatment Resistant Depression, by Forms of Treatment USD Million (2021-2026)
  • Table 121. Japan Treatment Resistant Depression, by Signs of Depression USD Million (2021-2026)
  • Table 122. Japan Treatment Resistant Depression, by Medication USD Million (2021-2026)
  • Table 123. Japan Treatment Resistant Depression, by Forms of Treatment USD Million (2021-2026)
  • Table 124. India Treatment Resistant Depression, by Signs of Depression USD Million (2021-2026)
  • Table 125. India Treatment Resistant Depression, by Medication USD Million (2021-2026)
  • Table 126. India Treatment Resistant Depression, by Forms of Treatment USD Million (2021-2026)
  • Table 127. South Korea Treatment Resistant Depression, by Signs of Depression USD Million (2021-2026)
  • Table 128. South Korea Treatment Resistant Depression, by Medication USD Million (2021-2026)
  • Table 129. South Korea Treatment Resistant Depression, by Forms of Treatment USD Million (2021-2026)
  • Table 130. Taiwan Treatment Resistant Depression, by Signs of Depression USD Million (2021-2026)
  • Table 131. Taiwan Treatment Resistant Depression, by Medication USD Million (2021-2026)
  • Table 132. Taiwan Treatment Resistant Depression, by Forms of Treatment USD Million (2021-2026)
  • Table 133. Australia Treatment Resistant Depression, by Signs of Depression USD Million (2021-2026)
  • Table 134. Australia Treatment Resistant Depression, by Medication USD Million (2021-2026)
  • Table 135. Australia Treatment Resistant Depression, by Forms of Treatment USD Million (2021-2026)
  • Table 136. Rest of Asia-Pacific Treatment Resistant Depression, by Signs of Depression USD Million (2021-2026)
  • Table 137. Rest of Asia-Pacific Treatment Resistant Depression, by Medication USD Million (2021-2026)
  • Table 138. Rest of Asia-Pacific Treatment Resistant Depression, by Forms of Treatment USD Million (2021-2026)
  • Table 139. Europe Treatment Resistant Depression, by Country USD Million (2021-2026)
  • Table 140. Europe Treatment Resistant Depression, by Signs of Depression USD Million (2021-2026)
  • Table 141. Europe Treatment Resistant Depression, by Medication USD Million (2021-2026)
  • Table 142. Europe Treatment Resistant Depression, by Forms of Treatment USD Million (2021-2026)
  • Table 143. Germany Treatment Resistant Depression, by Signs of Depression USD Million (2021-2026)
  • Table 144. Germany Treatment Resistant Depression, by Medication USD Million (2021-2026)
  • Table 145. Germany Treatment Resistant Depression, by Forms of Treatment USD Million (2021-2026)
  • Table 146. France Treatment Resistant Depression, by Signs of Depression USD Million (2021-2026)
  • Table 147. France Treatment Resistant Depression, by Medication USD Million (2021-2026)
  • Table 148. France Treatment Resistant Depression, by Forms of Treatment USD Million (2021-2026)
  • Table 149. Italy Treatment Resistant Depression, by Signs of Depression USD Million (2021-2026)
  • Table 150. Italy Treatment Resistant Depression, by Medication USD Million (2021-2026)
  • Table 151. Italy Treatment Resistant Depression, by Forms of Treatment USD Million (2021-2026)
  • Table 152. United Kingdom Treatment Resistant Depression, by Signs of Depression USD Million (2021-2026)
  • Table 153. United Kingdom Treatment Resistant Depression, by Medication USD Million (2021-2026)
  • Table 154. United Kingdom Treatment Resistant Depression, by Forms of Treatment USD Million (2021-2026)
  • Table 155. Netherlands Treatment Resistant Depression, by Signs of Depression USD Million (2021-2026)
  • Table 156. Netherlands Treatment Resistant Depression, by Medication USD Million (2021-2026)
  • Table 157. Netherlands Treatment Resistant Depression, by Forms of Treatment USD Million (2021-2026)
  • Table 158. Rest of Europe Treatment Resistant Depression, by Signs of Depression USD Million (2021-2026)
  • Table 159. Rest of Europe Treatment Resistant Depression, by Medication USD Million (2021-2026)
  • Table 160. Rest of Europe Treatment Resistant Depression, by Forms of Treatment USD Million (2021-2026)
  • Table 161. MEA Treatment Resistant Depression, by Country USD Million (2021-2026)
  • Table 162. MEA Treatment Resistant Depression, by Signs of Depression USD Million (2021-2026)
  • Table 163. MEA Treatment Resistant Depression, by Medication USD Million (2021-2026)
  • Table 164. MEA Treatment Resistant Depression, by Forms of Treatment USD Million (2021-2026)
  • Table 165. Middle East Treatment Resistant Depression, by Signs of Depression USD Million (2021-2026)
  • Table 166. Middle East Treatment Resistant Depression, by Medication USD Million (2021-2026)
  • Table 167. Middle East Treatment Resistant Depression, by Forms of Treatment USD Million (2021-2026)
  • Table 168. Africa Treatment Resistant Depression, by Signs of Depression USD Million (2021-2026)
  • Table 169. Africa Treatment Resistant Depression, by Medication USD Million (2021-2026)
  • Table 170. Africa Treatment Resistant Depression, by Forms of Treatment USD Million (2021-2026)
  • Table 171. North America Treatment Resistant Depression, by Country USD Million (2021-2026)
  • Table 172. North America Treatment Resistant Depression, by Signs of Depression USD Million (2021-2026)
  • Table 173. North America Treatment Resistant Depression, by Medication USD Million (2021-2026)
  • Table 174. North America Treatment Resistant Depression, by Forms of Treatment USD Million (2021-2026)
  • Table 175. United States Treatment Resistant Depression, by Signs of Depression USD Million (2021-2026)
  • Table 176. United States Treatment Resistant Depression, by Medication USD Million (2021-2026)
  • Table 177. United States Treatment Resistant Depression, by Forms of Treatment USD Million (2021-2026)
  • Table 178. Canada Treatment Resistant Depression, by Signs of Depression USD Million (2021-2026)
  • Table 179. Canada Treatment Resistant Depression, by Medication USD Million (2021-2026)
  • Table 180. Canada Treatment Resistant Depression, by Forms of Treatment USD Million (2021-2026)
  • Table 181. Mexico Treatment Resistant Depression, by Signs of Depression USD Million (2021-2026)
  • Table 182. Mexico Treatment Resistant Depression, by Medication USD Million (2021-2026)
  • Table 183. Mexico Treatment Resistant Depression, by Forms of Treatment USD Million (2021-2026)
  • Table 184. Research Programs/Design for This Report
  • Table 185. Key Data Information from Secondary Sources
  • Table 186. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Treatment Resistant Depression: by Forms of Treatment USD Million (2015-2020)
  • Figure 5. South America Treatment Resistant Depression Share (%), by Country
  • Figure 6. Asia Pacific Treatment Resistant Depression Share (%), by Country
  • Figure 7. Europe Treatment Resistant Depression Share (%), by Country
  • Figure 8. MEA Treatment Resistant Depression Share (%), by Country
  • Figure 9. North America Treatment Resistant Depression Share (%), by Country
  • Figure 10. Global Treatment Resistant Depression share by Players 2020 (%)
  • Figure 11. Global Treatment Resistant Depression share by Players (Top 3) 2020(%)
  • Figure 12. Global Treatment Resistant Depression share by Players (Top 5) 2020(%)
  • Figure 13. BCG Matrix for key Companies
  • Figure 14. Bristol Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 15. Bristol Myers Squibb Company (United States) Revenue: by Geography 2020
  • Figure 16. Janssen Pharmaceuticals, Inc. (Belgium) Revenue, Net Income and Gross profit
  • Figure 17. Janssen Pharmaceuticals, Inc. (Belgium) Revenue: by Geography 2020
  • Figure 18. Otsuka Pharmaceutical Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 19. Otsuka Pharmaceutical Co., Ltd. (Japan) Revenue: by Geography 2020
  • Figure 20. Mylan Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Mylan Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 22. Pfizer, Inc (United State) Revenue, Net Income and Gross profit
  • Figure 23. Pfizer, Inc (United State) Revenue: by Geography 2020
  • Figure 24. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 26. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 27. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 28. Wyeth (United States) Revenue, Net Income and Gross profit
  • Figure 29. Wyeth (United States) Revenue: by Geography 2020
  • Figure 30. Validus Pharmaceuticals LLC (United States) Revenue, Net Income and Gross profit
  • Figure 31. Validus Pharmaceuticals LLC (United States) Revenue: by Geography 2020
  • Figure 32. Global Treatment Resistant Depression: by Forms of Treatment USD Million (2021-2026)
  • Figure 33. South America Treatment Resistant Depression Share (%), by Country
  • Figure 34. Asia Pacific Treatment Resistant Depression Share (%), by Country
  • Figure 35. Europe Treatment Resistant Depression Share (%), by Country
  • Figure 36. MEA Treatment Resistant Depression Share (%), by Country
  • Figure 37. North America Treatment Resistant Depression Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Bristol Myers Squibb Company (United States)
  • Janssen Pharmaceuticals, Inc. (Belgium)
  • Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Mylan Pharmaceuticals, Inc. (United States)
  • Pfizer, Inc (United State)
  • Novartis AG (Switzerland)
  • Eli Lilly and Company (United States)
  • Wyeth (United States)
  • Validus Pharmaceuticals LLC (United States)
Select User Access Type

Key Highlights of Report


Oct 2021 222 Pages 56 Tables Base Year: 2020 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Treatment Resistant Depression Market Quantitative research analysis
Global Treatment Resistant Depression Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Treatment Resistant Depression market is expected to see a CAGR of % during projected year 2020 to 2026.
Top performing companies in the Global Treatment Resistant Depression market are Bristol Myers Squibb Company (United States), Janssen Pharmaceuticals, Inc. (Belgium), Otsuka Pharmaceutical Co., Ltd. (Japan), Mylan Pharmaceuticals, Inc. (United States), Pfizer, Inc (United State), Novartis AG (Switzerland), Eli Lilly and Company (United States), Wyeth (United States) and Validus Pharmaceuticals LLC (United States), to name a few.
"High risk of depression in teenager and older adults" is seen as one of major influencing trends for Treatment Resistant Depression Market during projected period 2020-2026.

Know More About Global Treatment Resistant Depression Market Report?

Have a Query? Click Here

Other Related Reports

Trauma Fixation - Comprehensive Study by Type (Internal Fixation, External Fixation), Application (Shoulder Fracture, Wrist Fracture, Femur Fracture, Ankle Fracture, Deformity Fracture, Others), End ...
$ 3650
Ocular Genetic Diagnostics Comprehensive Study by Test Methodologies (Next-generation Sequencing (NGS), Multiplex Ligation-Dependent Probe Amplification (MLPA), Fragment Analysis PCR for Repeat Expan...
$ 3750
Diabetes Associated Ophthalmic Treatment Comprehensive Study by Type (Drugs, Devices), Application (Children, Adults), Disease Type (Diabetic Retinopathy, Diabetic Macular Edema, Cataracts, Glaucoma)...
$ 3350
Pelvic Ring Fixation Comprehensive Study by Type (Type A, Type B, Type C), Indication (Pubic Symphysis Disruption, Sacroiliac Dislocation, Sacrum Fracture, Others), Type Of Fracture (Internal Pelvic...
$ 3750
Down syndrome Comprehensive Study by Type (Trisomy 21 (Nondisjunction), Mosaicism, Translocation), Disorder Severity (Mild Down Syndrome (IQ: 50–69), Moderate Down Syndrome (IQ: 35–50), Severe Down S...
$ 3650
Fibrosarcoma Treatment Comprehensive Study by Type (Infantile/Congenital-Type Fibrosarcoma, Adult-Type Fibrosarcoma), Technology (X-Ray, Computed Tomography (Ct), Magnetic Resonance Imaging (Mri), Bo...
$ 3750